# Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

> **NCT02222948** · PHASE2 · TERMINATED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 112 (actual)

## Conditions studied

- Relapsing-remitting Multiple Sclerosis

## Interventions

- **DRUG:** Vatelizumab
- **DRUG:** Placebo (for Vatelizumab)

## Key facts

- **NCT ID:** NCT02222948
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-09
- **Primary completion:** 2016-04
- **Final completion:** 2016-07
- **Target enrollment:** 112 (ACTUAL)
- **Why stopped:** Study discontinued based on planned interim analysis of the primary endpoint. Not linked to any safety concern.
- **Last updated:** 2016-12-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222948, "Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02222948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*